Prognostic factors, treatment, and survival in cutaneous pleomorphic sarcoma - 23/07/20
Abstract |
Background |
Limited information exists on the influence of demographics, tumor characteristics, and treatment on survival in cutaneous pleomorphic sarcoma (CPS).
Objective |
To describe incidence rates and prognostic factors affecting survival in CPS.
Methods |
National Cancer Institute's Surveillance, Epidemiology, and End Results data (1972-2013) was analyzed for 2423 patients with CPS diagnoses.
Results |
The age-adjusted incidence rate was 0.152 cases/100,000 person-years and was 4.5-fold higher in male than female patients. Male sex, white race, and increasing age >40 years were significantly associated with decreased overall survival. Head and neck tumors, tumors >15 mm, and tumors with grade III or IV histology were associated with significantly decreased survival. Surgical excision had a survival benefit compared with no treatment. Radiation therapy did not provide a survival benefit. Patients with localized disease had the greatest survival followed by regional and distant disease.
Limitations |
Surveillance, Epidemiology, and End Results data might not be reflective of all CPS patients. Recurrences, restaging, or other nonmortality events over time were not tracked.
Conclusion |
Tumor size, grade, sex, age at diagnosis, and race appear to influence survival as prognostic factors in CPS. Surgical tumor extirpation provides a survival benefit over no treatment whereas primary or adjuvant radiation does not provide a survival benefit.
Le texte complet de cet article est disponible en PDF.Key words : epidemiology, demographics, prognostic factors, treatment, undifferentiated pleomorphic sarcoma
Abbreviations used : CI, DSS, FNCLCC, HR, ICD-O, MMS, NCI, SEER
Plan
Funding sources: None. |
|
Conflicts of interest: None disclosed. |
Vol 83 - N° 2
P. 388-396 - août 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?